{"protocolSection": {"identificationModule": {"nctId": "NCT03200860", "orgStudyIdInfo": {"id": "2017-001679-22"}, "organization": {"fullName": "University Medical Center Groningen", "class": "OTHER"}, "briefTitle": "Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure", "officialTitle": "Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)", "acronym": "EMPA-RESPONSE"}, "statusModule": {"statusVerifiedDate": "2024-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-12-18", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-09-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-09-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-06-23", "studyFirstSubmitQcDate": "2017-06-26", "studyFirstPostDateStruct": {"date": "2017-06-27", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-01-08", "resultsFirstSubmitQcDate": "2020-02-09", "resultsFirstPostDateStruct": {"date": "2020-02-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-04-16", "lastUpdatePostDateStruct": {"date": "2024-04-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University Medical Center Groningen", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide. Short term mortality and rehospitalization are extremely high (20-30% within 3-6 months) and there is no therapy available that improves clinical outcome in these patients. Empagliflozin is a selective inhibitor of sodium glucose co-transporter with diuretic and renal- protective properties. In patients with type 2 diabetes at high risk for cardiovascular events, empagliflozin reduced the risk of hospitalization for heart failure by 35%. Based on the promising pharmacological profile of empagliflozin in relation to the needs for treatment of acute decompensated heart failure, we hypothesize that empagliflozin exerts positive effects in acute decompensated heart failure, with or without diabetes,\n\nThis is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.", "detailedDescription": "This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.\n\nTreatment will be continued until 30 days after index event, and primary efficacy measurements will be carried out during hospitalization and safety events until 60 days after index hospitalisation."}, "conditionsModule": {"conditions": ["Heart Failure Acute", "Heart Failure\uff0cCongestive", "Heart Failure; With Decompensation"], "keywords": ["heart failure", "diuretic response", "empagliflozin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "randomized, placebo-controlled, double-blind, parallel group, multicenter study", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "double blind, placebo controlled", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 80, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Empagliflozin", "type": "ACTIVE_COMPARATOR", "description": "Empagliflozin 10 mg daily, oral, 30 days", "interventionNames": ["Drug: Empagliflozin 10 MG"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Matching Placebo 10 mg daily, oral, 30 days", "interventionNames": ["Drug: Placebo Oral Tablet"]}], "interventions": [{"type": "DRUG", "name": "Empagliflozin 10 MG", "description": "10 mg daily, oral, 30 days", "armGroupLabels": ["Empagliflozin"]}, {"type": "DRUG", "name": "Placebo Oral Tablet", "description": "Matching Placebo, 10 mg daily, oral, 30 days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Dyspnea", "description": "Change in Dyspnea on VAS analogue scale (AUC)\n\nVAS Score is a measure/scale where patients on a scale from 0 to 100 can assign their current dyspnea score. 0 means there can be no worse dyspnea, 100 means it cannot get any better (perfect).\n\nThe change in Dyspnea VAS means higher score is better outcomes.\n\nIndividual changes in VAS score are be visualized (virtually) as a curve where the X-axis shows study day baseline to day 4, and y-axis shows VAS score. Using this approach, area under the curves for each study day (trapezoids) can be calculated, and added together, resulting in an overall VAS AUC score (mmxh) and change in VAS can be caculated", "timeFrame": "From baseline to Day 4"}, {"measure": "Diuretic Response", "description": "Weight change from baseline per 40 mg of Furosemide equivalent", "timeFrame": "Total weight change from baseline to Day 4"}, {"measure": "Length of Stay", "description": "Hospital stay of Index admission", "timeFrame": "within 60 days"}, {"measure": "Plasma NTproBNP", "description": "Change in NTproBNP", "timeFrame": "From baseline to Day 4"}], "secondaryOutcomes": [{"measure": "Death and/or Heart Failure Re-admission", "description": "Death and/or heart failure re-admission at day 30", "timeFrame": "Day 30"}, {"measure": "Inhospital Worsening Heart Failure, All Cause Mortality or Heart Failure Readmission at Day 60", "description": "Inhospital Worsening Heart Failure or All Cause mortality or Heart Failure Readmission at day 60", "timeFrame": "60 days"}, {"measure": "All Cause Mortality", "description": "All Cause Mortality at 60 days", "timeFrame": "60 day"}], "otherOutcomes": [{"measure": "Serious Adverse Events", "description": "SAE including all cause mortality. Per request Clintrials.gov different from Protocol definition", "timeFrame": "60 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female \\>18 years of age; Women of non-child-bearing potential must have a documentation of surgical sterilization (hysterectomy and/or bilateral oophorectomy) OR must have experienced menopause (no menses for \\>12 months). Women of child bearing potential must have a negative pregnancy test, AND must use highly effective methods of contraception during treatment with IP plus 5 days after the end of study drug administration.\n* Hospitalized for AHF; AHF is defined as including all of the followings measured at any time between presentation (including the emergency department) and the end of screening:\n\n  1. Dyspnea at rest or with minimal exertion\n  2. Signs of congestion, such as edema, rales, and/or congestion on chest radiograph\n  3. BNP \u2265350 pg/mL or NT-proBNP \u22651,400 pg/mL (for patients with AF: BNP\u2265500 pg/mL or NT-proBNP \u22652,000 pg/mL)\n  4. Treated with loop diuretics at screening\n* Able to be randomized within 24 hours from presentation to the hospital\n* Able and willing to provide freely given written informed consent\n* eGFR (CKD-EPI) \u226530 ml/min/1.73m2 between presentation and randomization\n\nExclusion Criteria:\n\n* Diabetes Mellitus Type I\n* Dyspnea primarily due to non-cardiac causes\n* Cardiogenic shock\n* Acute coronary syndrome within 30 days prior to randomization\n* Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization\n* Signs of keto-acidosis and/or hyperosmolar hyperglaecemic syndrome (pH\\>7.30 and glucose \\>15 mmol/L and HCO3\\>18 mmol/L)\n* Pregnant or nursing (lactating) women\n* Current participation in any interventional study\n* Inability to follow instructions or comply with follow-up procedures\n* Any other medical conditions that may put the patient at risk or influence study results in the investigator's opinion, or that the investigator deems unsuitable for the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Adriaan Voors, Prof. Dr.", "affiliation": "University Medical Center Groningen", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Jeroen Bosch Ziekenhuis", "city": "Den Bosch", "state": "Brabant", "country": "Netherlands", "geoPoint": {"lat": 51.27, "lon": 5.59167}}, {"facility": "TREANT Zorggroep", "city": "Emmen", "state": "Drenthe", "country": "Netherlands", "geoPoint": {"lat": 52.77917, "lon": 6.90694}}, {"facility": "Antonius Ziekenhuis", "city": "Sneek", "state": "Friesland", "country": "Netherlands", "geoPoint": {"lat": 53.03297, "lon": 5.6589}}, {"facility": "ISALA Klinieken", "city": "Zwolle", "state": "Overijssel", "country": "Netherlands", "geoPoint": {"lat": 52.5125, "lon": 6.09444}}, {"facility": "University Medical Center Groningen", "city": "Groningen", "zip": "9700RB", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}]}, "referencesModule": {"references": [{"pmid": "26378978", "type": "BACKGROUND", "citation": "Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17."}, {"pmid": "27299675", "type": "BACKGROUND", "citation": "Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "FG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "39"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "40"}, {"groupId": "FG001", "numSubjects": "39"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "BG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "79"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "16"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "63"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79", "lowerLimit": "73", "upperLimit": "83"}, {"groupId": "BG001", "value": "73", "lowerLimit": "61", "upperLimit": "83"}, {"groupId": "BG002", "value": "76", "lowerLimit": "68", "upperLimit": "83"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "53"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "79"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Netherlands", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "79"}]}]}]}, {"title": "NTproBNP", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "pg/mL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4406", "lowerLimit": "2873", "upperLimit": "6979"}, {"groupId": "BG001", "value": "6168", "lowerLimit": "3180", "upperLimit": "10489"}, {"groupId": "BG002", "value": "4918", "lowerLimit": "3062", "upperLimit": "9555"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Dyspnea", "description": "Change in Dyspnea on VAS analogue scale (AUC)\n\nVAS Score is a measure/scale where patients on a scale from 0 to 100 can assign their current dyspnea score. 0 means there can be no worse dyspnea, 100 means it cannot get any better (perfect).\n\nThe change in Dyspnea VAS means higher score is better outcomes.\n\nIndividual changes in VAS score are be visualized (virtually) as a curve where the X-axis shows study day baseline to day 4, and y-axis shows VAS score. Using this approach, area under the curves for each study day (trapezoids) can be calculated, and added together, resulting in an overall VAS AUC score (mmxh) and change in VAS can be caculated", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmxh", "timeFrame": "From baseline to Day 4", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1264", "spread": "1211"}, {"groupId": "OG001", "value": "1650", "spread": "1240"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.18", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "PRIMARY", "title": "Diuretic Response", "description": "Weight change from baseline per 40 mg of Furosemide equivalent", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg/40 mg Furosemide equivalent at day 4", "timeFrame": "Total weight change from baseline to Day 4", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "37"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.35", "spread": "0.44"}, {"groupId": "OG001", "value": "-0.12", "spread": "1.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.37", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "PRIMARY", "title": "Length of Stay", "description": "Hospital stay of Index admission", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "days", "timeFrame": "within 60 days", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "38"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8", "lowerLimit": "6", "upperLimit": "10"}, {"groupId": "OG001", "value": "8", "lowerLimit": "6", "upperLimit": "9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.58", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "PRIMARY", "title": "Plasma NTproBNP", "description": "Change in NTproBNP", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% change in NTproBNP at day 4", "timeFrame": "From baseline to Day 4", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-46", "spread": "32"}, {"groupId": "OG001", "value": "-42", "spread": "31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.63", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Death and/or Heart Failure Re-admission", "description": "Death and/or heart failure re-admission at day 30", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 30", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.31", "statisticalMethod": "Regression, Logistic"}]}, {"type": "SECONDARY", "title": "Inhospital Worsening Heart Failure, All Cause Mortality or Heart Failure Readmission at Day 60", "description": "Inhospital Worsening Heart Failure or All Cause mortality or Heart Failure Readmission at day 60", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "60 days", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.014", "statisticalMethod": "Regression, Logistic"}]}, {"type": "SECONDARY", "title": "All Cause Mortality", "description": "All Cause Mortality at 60 days", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "60 day", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Serious Adverse Events", "description": "SAE including all cause mortality. Per request Clintrials.gov different from Protocol definition", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "60 days", "groups": [{"id": "OG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days"}, {"id": "OG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "39"}]}], "classes": [{"title": "Cardiovascular", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Respiratory/Pulmonary", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Renal/Urinary", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Psychiatric", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Infectious", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "All Cause Mortality", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "60 days", "eventGroups": [{"id": "EG000", "title": "Empagliflozin", "description": "Empagliflozin 10 mg daily, oral, 30 days\n\nEmpagliflozin 10 MG: 10 mg daily, oral, 30 days", "deathsNumAffected": 1, "deathsNumAtRisk": 40, "seriousNumAffected": 8, "seriousNumAtRisk": 40, "otherNumAffected": 29, "otherNumAtRisk": 40}, {"id": "EG001", "title": "Placebo", "description": "Matching Placebo 10 mg daily, oral, 30 days\n\nPlacebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days", "deathsNumAffected": 3, "deathsNumAtRisk": 39, "seriousNumAffected": 10, "seriousNumAtRisk": 39, "otherNumAffected": 31, "otherNumAtRisk": 39}], "seriousEvents": [{"term": "Worsening Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 39}]}, {"term": "Worsening Renal Function", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}]}, {"term": "Acute Kidney Injury", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}]}, {"term": "Angioedema", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}]}, {"term": "Hypovolemic shock", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}]}, {"term": "Delirium", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}]}, {"term": "Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}]}, {"term": "S. Aureus Bacteremia", "organSystem": "Infections and infestations", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}]}, {"term": "Syncope", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}]}, {"term": "Respiratory Failure", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}]}], "otherEvents": [{"term": "Cardiovascular", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 17, "numAffected": 17, "numAtRisk": 39}]}, {"term": "Respiratory", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}]}, {"term": "Gastrointestinal", "organSystem": "Gastrointestinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 39}]}, {"term": "Renal/Urinary", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 15, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 39}]}, {"term": "Metabolic", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 39}]}, {"term": "Musculoskeletal", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 13, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 39}]}, {"term": "Other", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 40}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 39}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "* Limited number of patients\n* Screened many more patients then were included\n* no standardized protocol for inhospital treatment for HF"}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Prof. dr. A.A. Voors", "organization": "University Medical Center Groningen - Department of Cardiology", "email": "a.a.voors@umcg.nl", "phone": "0031503616161"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-10-20", "uploadDate": "2020-02-09T08:45", "filename": "Prot_000.pdf", "size": 417104}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-09-03", "uploadDate": "2020-02-09T08:50", "filename": "SAP_001.pdf", "size": 463151}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000570240", "term": "Empagliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M258082", "name": "Empagliflozin", "asFound": "Peer", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}